Active Biotech AB (publ) financials
Active Biotech AB (publ)
549300OJ44CLMRU8YE43 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 0 | SEK 0 |
| Administrative expenses | SEK 13.2M | SEK 13.9M |
| Operating profit (EBIT) | -SEK 39.8M | -SEK 46.5M |
| Net finance income / (cost) | SEK 443.0K | SEK 684.0K |
| Finance costs | SEK 209.0K | SEK 238.0K |
| Profit before tax | -SEK 39.4M | -SEK 45.8M |
| Income tax expense | SEK 0 | SEK 0 |
| Profit for the year | -SEK 39.4M | -SEK 45.8M |
| — attributable to owners | -SEK 39.4M | -SEK 45.8M |
| — attributable to NCI | SEK 0 | SEK 0 |
| Total comprehensive income | -SEK 39.4M | -SEK 45.8M |
| Per share | ||
| Basic EPS | SEK -0.09 | SEK -0.17 |
| Diluted EPS | SEK -0.09 | SEK -0.17 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 40.4M | -SEK 45.7M |
| Net cash from financing activities | SEK 31.6M | SEK 40.2M |
| Lease liability payments | SEK 1.6M | SEK 1.6M |
| Balance sheet | ||
| Total assets | SEK 43.2M | SEK 44.0M |
| Non-current assets | SEK 4.0M | SEK 5.3M |
| Right-of-use assets | SEK 3.4M | SEK 4.7M |
| Current assets | SEK 39.2M | SEK 38.7M |
| Cash & equivalents | SEK 27.4M | SEK 36.2M |
| Total equity | SEK 32.7M | SEK 30.7M |
| Non-current liabilities | SEK 1.5M | SEK 3.0M |
| Lease liabilities (non-current) | SEK 1.5M | SEK 3.0M |
| Current liabilities | SEK 8.9M | SEK 10.4M |
| Lease liabilities (current) | SEK 1.7M | SEK 1.5M |
| Derived metrics | ||
| Return on equity | -120.3% | -149.3% |
| Cash conversion ratio | 1.03× | 1.00× |
| Other reported items | ||
| Additional Paidin Capital | SEK 3.51B | SEK 3.47B |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 1.1M | -SEK 168.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -SEK 1.6M | -SEK 1.6M |
| Adjustments For Reconcile Profit Loss | SEK 1.7M | SEK 1.8M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 37.7M | -SEK 44.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | SEK 0 | SEK 0 |
| Comprehensive Income Attributable To Owners of Parent | -SEK 39.4M | -SEK 45.8M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 5.6M | SEK 5.4M |
| Current Prepayments and Current Accrued Income Other Than Current Contract Assets | SEK 2.3M | SEK 1.2M |
| Current Tax Assets Current | SEK 636.0K | SEK 636.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 0 | SEK 0 |
| Equity and Liabilities | SEK 43.2M | SEK 44.0M |
| Finance Income | SEK 652.0K | SEK 922.0K |
| Increase Decrease In Cash and Cash Equivalents | -SEK 8.8M | -SEK 5.6M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 13.0K | SEK 172.0K |
| Intangible Assets Other Than Goodwill | SEK 245.0K | SEK 245.0K |
| Issued Capital | SEK 6.4M | SEK 1.9M |
| Liabilities | SEK 10.4M | SEK 13.4M |
| Noncurrent Receivables | SEK 376.0K | SEK 376.0K |
| Other Comprehensive Income | SEK 0 | SEK 0 |
| Other Current Payables | SEK 197.0K | SEK 227.0K |
| Other Current Receivables | SEK 8.9M | SEK 619.0K |
| Payments For Share Issue Costs | SEK 2.0M | SEK 1.7M |
| Proceeds From Issuing Shares | SEK 35.2M | SEK 43.5M |
| Research and Development Expense | SEK 26.7M | SEK 32.5M |
| Retained Earnings | -SEK 3.48B | -SEK 3.44B |
| Trade and Other Current Payables To Trade Suppliers | SEK 1.5M | SEK 3.2M |
Every line item above is a fact tagged in Active Biotech AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.